Leadership Series: A talk by Dr Sharvil Patel
Dr Sharvil Patel is the Managing Director of Zydus Lifesciences Ltd., one of the leading global healthcare providers and the 4th largest life sciences company in India. He also officiates as the Chairman on the Board of Zydus Wellness Ltd., which is creating several novel experiences for the health conscious consumers and has a basket of niche products and iconic brands such as Sugar Free, Everyuth and Nutralite, Complan, Glucon D, and Nycil. With a specialisation in Chemical and Pharmaceutical Sciences from the University of Sunderland, U.K., and a doctorate also from the same university for his research work in Breast Cancer at Johns Hopkins, Bayview Medical Centre, USA, Dr Sharvil combines both pharma and research expertise.
His leadership inspires people to look at an expansive canvas of thoughts and ideas while focusing on a well-defined implementation roadmap. He was conferred the ‘40 Under 40 Most Influential Asians’ Award by the Asian Business & Social Forum 2018 (ABSF) and the Young Business Leader ’40 under Forty’ Award by ET Now in 2017.
Recently he has been conferred the ET Pharmaleader of the year at the ET Healthword India Pharma Awards. He has also been conferred the ‘The Economic Times Most Promising Business Leaders of Asia 2020-21’ Award,’ GenNext Entrepreneur of the Forbes India Leadership Awards (FILA) 2020-21’ by the Forbes India and ‘Young Turks Award’ by India Pharma Awards 2021.
Zydus is the only Indian lifesciences company to launch its own patented NCE – Lipaglyn, the novel drug to be approved for the treatment of diabetic dyslipidemia. The group is also the first in the world to announce a treatment for non-cirrhotic NASH, an unmet healthcare condition globally. Supporting the nation in the fight against the novel Coronavirus, Zydus is at the forefront manufacturing therapies and life saving drugs, exploring new therapy options through research, discovering vaccines and manufacturing diagnostic kits. The company also received the emergency use authorisation for the world’s first DNA plasmid vaccine ZyCoV-D.
